Danaher Reports First Quarter 2023 Results
Danaher Corporation announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders.
Uncategorized
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads Ventures
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announces the closing of a $38 million Series A+ financing.
FineHeart Granted First Two Patents in China for the FLOWMAKER®
FineHeart S.A announced that its first two patents have been granted in China by the CNIPA – China National Intellectual Property Administration -.
FineHeart Granted First Two Patents in China for the FLOWMAKER® Read More »
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited announces the activation of the first clinical trial site in the U.S. for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease.
Vamorolone NDA mid-cycle review meeting by FDA completed
Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce the successful completion of the mid-cycle review meeting by the U.S. Food and Drug Administration of the new drug application for vamorolone for the treatment of Duchenne muscular dystrophy.
Vamorolone NDA mid-cycle review meeting by FDA completed Read More »
Ascentage Pharma Passes GMP Compliance Audit by EU QP with Zero Deficiency, in an Achievement Signaling Global Recognition of the Company’s Quality Management System
Ascentage Pharma announced that it recently received a zero-deficiency report from the GMP compliance audit of Ascentage Pharma’s Global Manufacturing Center by a Qualified Person of the European Union.
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
ImmunityBio, Inc., a clinical-stage immunotherapy company, announced that Executive Chairman and Global Chief Scientific and Medical Officer Patrick Soon-Shiong, M.D., has been invited to deliver the 2023 David Packard Award Lecture at the Uniformed Services University of the Health Sciences.
IDEAYA Announces Pricing of Public Offering – April 25, 2023
IDEAYA Biosciences, Inc. announced the pricing of an underwritten public offering of common stock and pre-funded warrants.
IDEAYA Announces Pricing of Public Offering – April 25, 2023 Read More »
MAIA Biotechnology, Inc. Announces Pricing of Public Offering – April 25, 2023
MAIA Biotechnology, Inc. announced the pricing of an underwritten public offering of 2,222,200 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and other offering expenses.
MAIA Biotechnology, Inc. Announces Pricing of Public Offering – April 25, 2023 Read More »